EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
DON'T BUY

Pfizer Inc(PFE)

Nov 23, 2011
Pharmaceutical space is tough. Lipitor is a drug that is going off-patent which will reduce their income.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$18.45

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 21, 2011
The 3 sectors hated sectors in the US are financials, healthcare and technology. They have done a lot of smart things recently. They increased the dividend and announced a share buyback. Valuation is quite cheap and he is looking at this one.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$18.96

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 15, 2011
A good space. Defensive name. Prefers JNJ. Seeing higher lows this year. Could come down to a higher low. Ranked 5th on his list. Would hold it.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$19.87

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Oct 24, 2011
The whole pharma business is challenged. PFE is predicting lower revenues next year. Management is talking about breaking up the company. With Lipitor patent expiring, he would just sell it.
Photo of Gordon ReidGordon ReidUnlock Rating
$19.36

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 12, 2011
Suffering from loosing their patent on lipitor. Will be a pullback on earnings. Trying to reassess their businesses and potentially spinning some off. Not a big fan of large cap Pharma. Prefers diversified health care companies like Abbot.
Photo of Christine PooleChristine PooleUnlock Rating
$18.82

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 23, 2011
Debt rating cut but it doesn’t matter to him. They all have the patent cliff. He likes that they bought Wyeth who have a lot of drugs on patent. People say PFE is too big to make a difference if a new drug comes along so they are shrinking the company. Big, safe dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.45

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 28, 2011
Lipitor is coming off patent and accounts for a boat 20% of their revenues. Sales are expected to drop about 5% next year.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$19.36

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 22, 2011
Largest drug company in the world. Good pipeline, but they have been paring it down to focus on new drugs. Prefers Teva.
Photo of Richard FoglerRichard Fogler
No
Unlock Rating
$20.07

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jun 16, 2011
This would be his 2nd choice after Eli Lilly (LLY-N). Facing the issue of a patent cliff where drugs are coming off patent. Has about 4 drugs expecting to move into phase 3 trials. Very attractive multiple. Good dividend yield.
Photo of Mohsin BashirMohsin BashirUnlock Rating
$20.24

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 12, 2011
Largest global pharma. Likes it. Whole pharma sector has been suffering from a lack of new block buster drugs. This one is facing the expiration of the patent on their Lipitor drug but this is already reflected in the stock price. Have some very promising drugs in phase 2 and 3 clinical trials. Stock is not expensive and has a 4% yield.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$20.89

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 27, 2011
Has done well lately on the potential of it breaking up and selling off the pieces. The difficulty in the whole pharma sector is that it is tough to grow.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.63

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 06, 2011
Likes this one especially because they have announced they are going to downsize the company and shareholders will be rewarded for that. Selling a capsule manufacturing company for $2.5 billion.
Photo of Norman LevineNorman LevineUnlock Rating
$20.29

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 25, 2011
Drug sector is all suffering from same thing – drugs coming off patent faster than entering the pipeline. Are trying to rebuild themselves. They are all trying to get their costs down.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$20.35

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 24, 2011
Thinks it is turning around. Very good yield. Have a difficult time with some of the blockbuster drugs coming off patent.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$20.30

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Mar 15, 2011
Are breaking themselves up after a string of acquisitions. He sees this happening. Want to get rid of their generics.
Photo of Don ReedDon ReedUnlock Rating
$19.76

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 421 to 435 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica